A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
This study showed no significant difference in the development of the primary endpoint, Campylobacteriosis, between subjects treated with rifaximin or placebo. However, the difference in mean total loose stool output (mL) is significantly reduced in the rifaximin group, and within this group a reduction in the maximum volume of loose stools in 24 hours was also observed. Therefore, whilst rifaximin does not protect against Campylobacteriosis, this objective data relating to stool volumedoi:10.1093/ofid/ofv133.613 fatcat:yu35xtexpvdshay5je6v4qvqt4